Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial
PaperCitations, authors & open-access status
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 379 citations, 2021 year and green oa status.
379
Citations
2021
Year
green
OA Status